TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30384149

Group type: EXPERIMENTAL
Intervention: Uncertain evaluative threat condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative evaluative threat condition
Number of subjects: 0
Study: 27287207

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment (n = 179)
Number of subjects: 361
Study: 24974131

Group type: EXPERIMENTAL
Intervention: Acarbose (Arm A; n = 7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metformin (Arm B; n = 6)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pioglitazone (Arm C; n = 5)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (Arm D; n = 5)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall SVR in female patients receiving OHA
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall SVR in male patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Acarbose (Arm A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Metformin (Arm B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Pioglitazone (Arm C)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Per protocol analysis for Peginterferon alfa-2b plus ribavirin (Arm D)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients receiving OHA
Number of subjects: 23
Study: 23323329

Group type: EXPERIMENTAL
Intervention: Emoxipin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20549525

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy treatment for postpartum depression
Number of subjects: 176

Group type: COMPARATOR
Intervention: Never depressed postpartum women
Number of subjects: 176
Study: 18514501

Group type: EXPERIMENTAL
Intervention: PUFA supplementation for 15 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PUFA+MVM for 15 weeks (after initial 15 weeks)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Additional micronutrient supplementation
Number of subjects: 129
Study: 20590369

Group type: EXPERIMENTAL
Intervention: Acoustic wave therapy (AWT) using extracorporeal pulse activation technology (EPAT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated legs)
Number of subjects: 25
Study: 16324360

Group type: EXPERIMENTAL
Intervention: UTI 5000 U/kg given one hour after injury, 3 times/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: UTI 400,000 U IV drop bid for 7 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine treatment with fluid resuscitation and wound management, normal saline IV drop bid for 7 days
Number of subjects: 52
Study: 12193353

Group type: EXPERIMENTAL
Intervention: Active warming at 52 degrees C
Number of subjects: 140

Group type: COMPARATOR
Intervention: Passive insulation (heater not activated)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 140

Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 140
Study: 9502350

Group type: EXPERIMENTAL
Intervention: Atropine (A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: First cycle ergometer test (F)
Number of subjects: 20
Study: 8018759

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional serum therapy
Number of subjects: 84
Study: 2692645

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative radiotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 500
Study: 4920816

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 11739866

Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) oil (target dose 10 g/d) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ordinary TG cooking oil (control group)
Number of subjects: 16
Study: 30561577

Group type: EXPERIMENTAL
Intervention: Biannual azithromycin distributions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30097357

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival adjusted for quality of life
Number of subjects: 0
Study: 26248651

Group type: EXPERIMENTAL
Intervention: Cancer Coping Online (CCO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Web-based attention control
Number of subjects: 60
Study: 25277215

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 0
Study: 22364141

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) 400/100 mg BID + raltegravir (RAL) 400 mg BID
Number of subjects: 60

Group type: COMPARATOR
Intervention: sHAART
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) + raltegravir (RAL)
Number of subjects: 60
Study: 20163864

Group type: EXPERIMENTAL
Intervention: Bimatoprost gel suspension applied to the base of the eyelashes every evening for 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (normal saline gel suspension) applied to the base of the eyelashes every evening for 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (bimatoprost and placebo)
Number of subjects: 19
Study: 18069761

Group type: EXPERIMENTAL
Intervention: Urine trypsinogen-2 dipstick test (UTDT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (non-pancreatic causes)
Number of subjects: 92
Study: 16006724

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 40
Study: 12422138

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 108
Study: 10359733

Group type: EXPERIMENTAL
Intervention: Eptifibatide (GP IIb/IIIa inhibitor)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eptifibatide or Placebo
Number of subjects: 100
Study: 7576753

Group type: EXPERIMENTAL
Intervention: Lumpectomy with radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSABP-B06 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage I good prognosis patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage I poor prognosis patients
Number of subjects: 0
Study: 1835293

Group type: EXPERIMENTAL
Intervention: Intervention with smoking cessation and placebo inhaler
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Intervention with smoking cessation and ipratropium bromide
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study: 6269234

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ranitidine (follow-up after initial treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (follow-up after initial treatment)
Number of subjects: 50
Study: 31839104

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin preoperative neoadjuvant chemotherapy (Group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Surgical treatment after preoperative examination (Group B)
Number of subjects: 82
Study: 28711708

Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 26239086

Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF)
Number of subjects: 22
Study: 24307269

Group type: EXPERIMENTAL
Intervention: Neurexal (test product)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lyrica (reference product)
Number of subjects: 23
Study: 22447014

Group type: EXPERIMENTAL
Intervention: Combination pill (losartan 50mg/hydrochlorothiazide 12.5mg)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (angiotensin receptor blocker and thiazide diuretic)
Number of subjects: 207
Study: 19687338

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 3,375 with hot flashes)
Number of subjects: 48335

Group type: COMPARATOR
Intervention: Control group (n = 3,375 with hot flashes)
Number of subjects: 48335

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 45,160 without hot flashes)
Number of subjects: 48335

Group type: COMPARATOR
Intervention: Control group (n = 45,160 without hot flashes)
Number of subjects: 48335

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 48335

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48335
Study: 17524942

Group type: EXPERIMENTAL
Intervention: MMF 500 (500 mg single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CellCept (500 mg single oral dose)
Number of subjects: 0
Study: 15205961

Group type: EXPERIMENTAL
Intervention: Weight Lifting (WL) for 60 min at 70‐75% of 1‐RM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Running (R) for 60 min at 70‐75% of maximal oxygen intake
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise (C)
Number of subjects: 10
Study: 11986597

Group type: EXPERIMENTAL
Intervention: Intraoperative intrapleural hypotonic cisplatin treatment (50 microg/mL in distilled water for 15 minutes)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study: 9772139

Group type: EXPERIMENTAL
Intervention: corn oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: beef tallow
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rice bran oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: canola oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: olive oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: all dietary phases pooled
Number of subjects: 14
Study: 7648281

Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing HIV envelope protein gp160LAI (HIVAC-1e) plus 640 micrograms recombinant baculovirus-expressed gp160LAI in alum (boosted 1-13 months later)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing HIV envelope protein gp160LAI (HIVAC-1e)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subunit gp160LAI (640 micrograms in alum, 4 immunizations at 0, 1, 6, and 12 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (5 total)
Number of subjects: 10
Study: 2699994

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 to 0.5 micrograms daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 603844

Group type: EXPERIMENTAL
Intervention: Duogastrone (carbenoxolone sodium) 50 mg qid for 6 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo capsules qid for 6 weeks
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Duogastrone (carbenoxolone sodium)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 31278996

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Assisted Referral to Care (ARC)
Number of subjects: 185
Study: 30990549

Group type: EXPERIMENTAL
Intervention: Workplace wellness program (8 modules focused on nutrition, physical activity, stress reduction)
Number of subjects: 32974

Group type: COMPARATOR
Intervention: Control group (no wellness programming)
Number of subjects: 32974
Study: 29243795

Group type: EXPERIMENTAL
Intervention: Recombinant LH (r‐LH) added to recombinant FSH (r‐FSH) in the late follicular phase starting the same day of GnRH-antagonist administration.
Number of subjects: 66
Study: 25880966

Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a home trainer equipped with gaming elements (exergaming)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-aerobic intervention (stretching, flexibility and relaxation exercises)
Number of subjects: 130
Study: 23859743

Group type: EXPERIMENTAL
Intervention: Knotless anastomosis with barbed suture (V‐Loc™ 180; Covidien)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Knot-tying anastomosis with 3/0 polyglactin sutures (Polysorb(®); Covidien)
Number of subjects: 60
Study: 21890753

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 65
Study: 19649649

Group type: EXPERIMENTAL
Intervention: 5 x 10 RM(Rel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 x 10 RM(Abs)
Number of subjects: 12
Study: 17623719

Group type: EXPERIMENTAL
Intervention: 1.3 g of EPA + DHA daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15154664

Group type: EXPERIMENTAL
Intervention: Radiotherapy before 90 days after surgery
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Radiotherapy after 90 days after surgery
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Chemotherapy with CMF regimens and radiotherapy before 90 days after surgery
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Chemotherapy with CMF regimens and radiotherapy after 90 days after surgery
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Overall local failure rate for group A
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Overall local failure rate for group B
Number of subjects: 590
Study: 11402634

Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release metformin hydrochloride tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release metformin hydrochloride product
Number of subjects: 0
Study: 9511024

Group type: EXPERIMENTAL
Intervention: Balanced protein/energy supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc, folate, and magnesium supplementation during gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional interventions (various types)
Number of subjects: 0
Study: 8582130

Group type: EXPERIMENTAL
Intervention: Acarbose taken at the beginning of the test meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acarbose taken 15 min after starting the test meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acarbose taken 30 min before the test meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control meal (no drug)
Number of subjects: 24
Study: 2172884

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy of 30 Gy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy of 50 Gy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups (30 Gy, 50 Gy, and chemotherapy alone)
Number of subjects: 91
Study: 720236

Group type: EXPERIMENTAL
Intervention: Combination of 75 mg dipyridamol and 330 mg acetylsalicylic acid, three times daily by mouth
Number of subjects: 101

Group type: COMPARATOR
Intervention: Acetylsalicylic acid alone at the same dosage
Number of subjects: 101
Study: 30874860

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28100203

Group type: EXPERIMENTAL
Intervention: VR exposure treatment with diaphragmatic breathing (six cycles per minute)
Number of subjects: 29

Group type: COMPARATOR
Intervention: VR exposure treatment without diaphragmatic breathing
Number of subjects: 29
Study: 25546032

Group type: COMPARATOR
Intervention: Ankle-brachial index (ABI)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Maximum interartery differences (MIAD) in systolic blood pressures
Number of subjects: 479
Study: 24352397

Group type: EXPERIMENTAL
Intervention: MBT technique for alignment and leveling
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal occlusion group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Malocclusion group
Number of subjects: 70
Study: 21435203

Group type: EXPERIMENTAL
Intervention: POCT-assisted diagnosis
Number of subjects: 369

Group type: COMPARATOR
Intervention: Conventional diagnosis
Number of subjects: 369
Study: 19474138

Group type: EXPERIMENTAL
Intervention: 100 mg ferrous sulfate
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 17276712

Group type: EXPERIMENTAL
Intervention: Montelukast (5mg chewable tablet once daily for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketotifen (1mg for 8 weeks)
Number of subjects: 50
Study: 15191819

Group type: EXPERIMENTAL
Intervention: Intramuscular dissection of perforators (DIEP flap)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (intact rectus abdominis muscles)
Number of subjects: 14
Study: 15569871

Group type: EXPERIMENTAL
Intervention: rFVIIa (10, 20, 40, 80, 120, or 160 microg/kg; n=6 per group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 48
Study: 10954759

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen per day
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 9077373

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (more than 800 g pure ethanol annually)
Number of subjects: 1924

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (weekend drinkers)
Number of subjects: 1924

Group type: EXPERIMENTAL
Intervention: Low HDLc (mean 0.94 mmol L‐1)
Number of subjects: 1924

Group type: EXPERIMENTAL
Intervention: Normal HDLc (mean 1.25 mmol L‐1)
Number of subjects: 1924

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 1924
Study: 8365006

Group type: EXPERIMENTAL
Intervention: Otovent device used three times a day for 3 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Observation group (control)
Number of subjects: 85
Study: 2941770

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2756308

Group type: EXPERIMENTAL
Intervention: Omnipaque
Number of subjects: 71

Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 71
Study: 31622944

Group type: EXPERIMENTAL
Intervention: Prevention of Post‐Rape Stress (PPRS)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Pleasant Imagery and Relaxation Information (PIRI)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 233
Study: 31011807

Group type: EXPERIMENTAL
Intervention: BFR (Blood Flow Restriction)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HYP (Hypoxia)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HBFR (Hypoxia + Blood Flow Restriction)
Number of subjects: 14

Group type: COMPARATOR
Intervention: NOR (Normoxia)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BFR
Number of subjects: 14
Study: 28433432

Group type: EXPERIMENTAL
Intervention: Low-Dose-Rate Prostate Brachytherapy (LDR-PB) boost
Number of subjects: 398

Group type: COMPARATOR
Intervention: Dose-Escalated External Beam Radiation Therapy (DE-EBRT) boost
Number of subjects: 398
Study: 25262788

Group type: EXPERIMENTAL
Intervention: niosomal methylene blue (NMB) gel
Number of subjects: 11

Group type: COMPARATOR
Intervention: unloaded (free) methylene blue (FMB) gel
Number of subjects: 11
Study: 24164685

Group type: EXPERIMENTAL
Intervention: Axillary vein approach
Number of subjects: 48

Group type: COMPARATOR
Intervention: Subclavian vein approach
Number of subjects: 48
Study: 21190450

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cell transplantation (BMC-Tx)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no cell therapy)
Number of subjects: 56
Study: 19614907

Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 17211875

Group type: EXPERIMENTAL
Intervention: Interpersonal profiles in MDD patients
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: MDD patients with depressive personality disorder
Number of subjects: 141
Study: 14759620

Group type: EXPERIMENTAL
Intervention: Filshie clip
Number of subjects: 40

Group type: COMPARATOR
Intervention: Falope ring
Number of subjects: 40
Study: 11253866

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cromolyn
Number of subjects: 0
Study: 9539056

Group type: EXPERIMENTAL
Intervention: Diclofenac monotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined treatment with Tramadol-retard and Naproxen
Number of subjects: 150
Study: 7925788

Group type: EXPERIMENTAL
Intervention: Prior adaptation to a grating pattern moving at between 1.5 and 4 cycles.s‐1 for 8 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior exposure to a flickering stimulus at a temporal frequency of 3.2 cycles.s‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior adapting gratings with varying contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motion‐dependent adaptive effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flicker‐dependent effect
Number of subjects: 0
Study: 2510677

Group type: EXPERIMENTAL
Intervention: APSAC (30 IU) administered by intravenous bolus injection over 2 to 5 minutes
Number of subjects: 116

Group type: COMPARATOR
Intervention: Streptokinase (SK) (1.5 million IU) administered by intravenous infusion over 60 minutes
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 116

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 116
Study: 803252

Group type: EXPERIMENTAL
Intervention: Adjuvant MOPP chemotherapy with irradiation
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combined treatment (Adjuvant MOPP chemotherapy with irradiation)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (without adjuvant MOPP chemotherapy)
Number of subjects: 213